Rangering i aksjer
#37811
Idogen AB (publ) is a Swedish biotechnology company specializing in the... Idogen AB (publ) is a Swedish biotechnology company specializing in the development of tolerogenic cell therapies. These innovative treatments are engineered to prevent a patient's immune system from attacking crucial elements, including biological agents, transplanted organs, and the body's own cells or tissues. The company's most advanced product in development is IDO 8, designed for individuals with severe haemophilia A who have developed neutralizing antibodies against their vital coagulation factor VIII treatment. Idogen is also developing IDO T, a tolerogenic cell therapy intended to prevent organ transplant rejection, primarily for kidney transplants, and IDO AID, aimed at treating autoimmune diseases. Established in 2008, the company is headquartered in Lund, Sweden.
Aksjekurs
$0.01345907
Sist synkronisert: 2024-07-12
Handel Idogen AB (publ) (IDOGEN)
Pris IDOGEN pris med markedsverdi på B
Markedsverdi av Idogen AB (publ)(IDOGEN)
Markedsverdi: $1.43M
Per August 2026 har Idogen AB (publ) en markedsverdi på $1.43M. Dette gjør Idogen AB (publ) til det 37811th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Idogen AB (publ) fra 2015 til 2026
IDOGEN sammenlignet med topp 5 mest populære stocks
| Pris på IDOGEN |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.452T
|
+381,741,842.27%
|
|
|
|
|
$4.490T
|
+314,392,894.12%
|
|
|
|
|
$4.162T
|
+291,453,291.30%
|
|
|
|
|
$3.676T
|
+257,418,856.56%
|
|
|
|
|
$2.833T
|
+198,370,668.95%
|
